echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The SNDA for LORBRENA's treatment of previously untreated APK-positive lung cancer has been given priority by the FDA

    The SNDA for LORBRENA's treatment of previously untreated APK-positive lung cancer has been given priority by the FDA

    • Last Update: 2021-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pfizer announced today that the U.S. Food and Drug Administration (FDA) has accepted a new drug application (sNDA) for LORBRENA ® as a first-line treatment for ALC-positive metastasis non-small cell lung cancer (NSCLC).
    approval of the SNDA is based on data from key CROWN studies.
    In fact, it has been previously reported that the new generation of lung cancer target drug Loratini: significantly improved progression-free survival of ALC-positive NSCLC patients LORBRENA is a third-generation ALC inhibitor specifically developed to inhibit the most common tumor mutations, these mutations drive resistance to current drugs, up to 40% of ALC-positive lung cancer patients have brain metastasis.
    Detailed results see: NEJM: "Head-to-head" Phase III study confirmed the treatment of ALK-positive non-small cell lung cancer, Laroteni significantly better than cytocinic non-small cell lung cancer (NSCLC) is still one of the highest mortality malignant tumors in humans, NSCLC in order of morbidity for adenocarcinoma, squamous cancer, large cell carcinoma and non-specific types.
    For most NSCLC patients, the current first-line treatment is platinum-based combination chemotherapy or the use of molecularly targeted drugs for specific populations, although most patients after pre-induced treatment can significantly improve clinical symptoms and quality of life, but most patients will relapse within the next year, a one-year survival rate of only 30%-50%.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.